Search

Home > New FDA Approvals > 016 - Alexion’s Soliris in myasthenia gravis; BrainStorm Cell Therapeutics Inc. patent for NurOwn technology for Parkinson's disease and amyotrophic lateral sclerosis; Scott Gottlieb, MD, promotes Orphan Drug Act.
Podcast: New FDA Approvals
Episode:

016 - Alexion’s Soliris in myasthenia gravis; BrainStorm Cell Therapeutics Inc. patent for NurOwn technology for Parkinson's disease and amyotrophic lateral sclerosis; Scott Gottlieb, MD, promotes Orphan Drug Act.
Category: Science & Medicine
Duration: 0
Publish Date: 2017-10-24 07:27:18
Description:

October 24, 2017

Today I talk about the following:

0.35 The FDA has approved Alexion Pharmaceuticals Inc.'s (ALXN) rare-disease drug, Soliris, for the treatment of adult patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

http://news.alexion.com/press-release/product-news/fda-approves-soliris-eculizumab-treatment-patients-generalized-myasthenia

3:14 BrainStorm Cell Therapeutics Inc. (BCLI) has expanded its patent portfolio to include a new US patent for its NurOwn technology for Parkinson's disease and amyotrophic lateral sclerosis.

http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=RssLanding&cat=news&id=2310390

4.18 Scott Gottlieb, MD, appointed to head the FDA in May, addressed the Rare Diseases & Orphan Products Breakthrough Summit. The National Organization for Rare Disorders (NORD) sponsored the meeting, which took place Oct. 16-17 in Washington, D.C. He said that "we need to make sure we can continue to build on the success of the Orphan Drug Act."

https://alsnewstoday.com/2017/10/23/nordsummit-fda-chief-speaks-of-agency-support-for-rare-disease-treatment-development/

Please visit us at nascentmc.com or email info@nascentmc.com if you need assistance with medical writing.
Total Play: 0